Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM – Get Free Report)’s share price traded down 1.3% during trading on Thursday . The stock traded as low as $18.38 and last traded at $18.38. 1,048 shares were traded during trading, a decline of 51% from the average session volume of 2,146 shares. The stock had previously closed at $18.62.
Amplify Treatments, Testing and Advancements ETF Stock Performance
The stock has a fifty day simple moving average of $18.53 and a two-hundred day simple moving average of $18.51. The stock has a market cap of $10.11 million, a PE ratio of 7.10 and a beta of 1.08.
About Amplify Treatments, Testing and Advancements ETF
The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.
Recommended Stories
- Five stocks we like better than Amplify Treatments, Testing and Advancements ETF
- Top Stocks Investing in 5G Technology
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- High Flyers: 3 Natural Gas Stocks for March 2022
- Progress Software Stock Back in the Green After Beating Forecasts
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Amplify Treatments Testing and Advancements ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Treatments Testing and Advancements ETF and related companies with MarketBeat.com's FREE daily email newsletter.
